5 results
The objective of the RADIANCE-HTN study is to demonstrate the efficacy and verify the safety of the Paradise System in two distinct populations of hypertensive subjects. Prior to randomization, subjects will be hypertensive in the absence of…
Primary objectives:To compare the efficacy of Adagrasib in combination with cetuximab versus chemotherapy (FOLFIRI or mFOLFOX6) administered in the second-line treatment setting to patients with CRC with KRAS G12C mutation.Secondary objectives:• To…
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be…
The primary goal of Part 3 of this study is to evaluate the safety, recommended phase 2 dose (RP2D), antitumor effect and PK of SAR442720 in combination with KRAS G12C inhibitor adagrasib, in participants with NSCLC with KRAS G12C mutationsPart-3a…
To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.